Update: Expectations high for 'positive early access'/adaptive licensing recommendations in UK
This article was originally published in SRA
Executive Summary
The expert group set up under the Strategy for UK Life Sciences to examine innovative approaches to regulation in healthcare is shortly due to publish "tangible and practical" recommendations on how the UK Medicines and Healthcare products Regulatory Agency might improve its approach to drug regulation.